Syngene International Limited has informed the Exchange regarding 'Revised Intimation of Conference Call for Analysts and Investors'.
Ref: Syn/CS/SE/Reg 30/2024-25/Jan/07
January 17, 2025
To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268
Dear Sir/Madam,
Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India
T +91 80 6891 8000 F +91 80 6775 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
Subject: Revised Intimation of Conference Call for Analysts and Investors
With reference to the intimation having reference no. Syn/CS/SE/Reg 30/2024-25/Jan/06 dated January 15, 2025, and in accordance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby submit the revised intimation regarding the conference call due to non-functioning of the hyperlink provided for the pre-registration facility in the previous intimation, which now has been rectified.
We would like to confirm that all other details related to the conference call will remain as previously stated and unchanged.
The above-mentioned www.syngeneintl.com.
information will also be available on the website of the Company
Request to kindly take this intimation on record.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
____________________ Priyadarshini Mahapatra Head Legal, Company Secretary & Compliance Officer
INVESTOR CONFERENCE CALL INVITE
Q3 FY 2024-25
Syngene’s Q3 FY2025 Results Conference Call
At 6:00 pm IST on 23rd January 2025
The management team of Syngene International Limited (“Syngene”) will organize a conference call for Analysts and Investors on Thursday, 23rd January 2025 at 6.00 pm IST following the announcement of financial results for the quarter ended December 31, 2024.
The call will be initiated with a brief management discussion on the Q3 FY2025 performance followed by an interactive Question & Answer session. Mr. Jonathan Hunt - Syngene’s Managing Director and Chief Executive Officer and other members of the senior management team will represent Syngene on the conference call.
Details of the conference call are as under:
Date:
Time:
Dial-in Numbers*
Primary Number
International Numbers
Thursday, 23rd January 2025
6:00 pm to 6:45 pm IST
+91 22 6280 1279
/ 91 22 7115 8180
USA – 18667462133
UK – 08081011573
Singapore – 8001012045
Hong Kong – 800964448
Australia – 0080014243444
Pre-registration Facility
(Diamond Pass™ link)
Step 1: Pre-register Click here . You will receive a passcode and a pin for the call on the registered email address.
Step 2: Dial into the call on the Conference Call date, enter the passcode
& pin as prompted. You will be directly connected to the call
*When using dial-in numbers mentioned please do so 10 minutes prior to the conference schedule to ensure that you are connected to your call in time
Syngene International: Putting Science to Work
Page 1
INVESTOR CONFERENCE CALL INVITE
Q3 FY 2024-25
Replay/Audio Facility
Dial in numbers: +91 22 71945757
Playback ID: 83711
The replay facility will be available from 23rd January 2025 till
30 January 2025
The audio facility will also be available on the corporate website:
https://syngeneintl.com/
Conference Call Transcript
Will be available within 7 working days of the call on the corporate
website: https://syngeneintl.com/
About Syngene
Syngene International Ltd. (BSE: 539268, NSE: SYNGENE, ISIN: INE 398R01022) is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene's more than 5600 scientists offer both skills and the capacity to deliver great science, robust data security, and world class manufacturing, at speed, to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Amgen, Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist discovery, development, and manufacturing facilities, Syngene works with biotech companies pursuing leading-edge science as well as multinationals, including GSK, Zoetis and Merck KGaA. For more details, visit www.syngeneintl.com For the Company’s latest Environmental, Social, and Governance (ESG)report, visit https://esgreport.syngeneintl.com
For further information, please contact:
Krishnan G / Nandini Agarwal P: +91 80 6891 9807 M: +919819992927 / 7838382527 E: krishnan.g@syngeneintl.com E: nandini.agarwal@syngeneintl.com
Disclaimer: Certain of the statements that may be made or discussed at the conference call may be forward- looking statements and/or based on management's current expectations and beliefs concerning future developments and their potential effects upon Syngene International Limited (Syngene) and its associates. There can be no assurance that future developments affecting Syngene, and its associates will be those anticipated by management. These forward-looking statements are not a guarantee of future performance and involve risks and uncertainties and there are important factors that could cause actual results to differ, possibly materially, from expectations reflected in such forward-looking statements. Syngene does not intend, and is under no obligation, to update any forward-looking statement made at the conference call.
Syngene International: Putting Science to Work
Page 2